KB803 not checked

Krystal Biotech, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein”In the company’s words, NCT07016750 on ClinicalTrials.gov
Tested for
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Main trialPhase 3
“KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).”In the company’s words, NCT07016750 on ClinicalTrials.gov

Other drugs for Dystrophic Epidermolysis Bullosa

All 8 drugs for Dystrophic Epidermolysis Bullosa

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Dec 2026 A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow KB803

Following is part of Solo: you see every change to KB803 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in